Shopping Cart
Remove All
Your shopping cart is currently empty
Samalizumab
😃Good
Catalog No. T78295Cas No. 1073059-33-2
Alias ALXN 6000
Samalizumab (ALXN 6000) is a humanized anti-CD200 monoclonal antibody that specifically targets the CD200 immunoregulatory cell surface protein, a member of the immunoglobulin superfamily which functions to dampen excessive immune responses and maintain self-tolerance, thereby establishing Samalizumab as an effective immune checkpoint inhibitor currently under investigation for the treatment of myeloma and B-cell chronic lymphocytic leukemia (CLL).
Samalizumab
Samalizumab
😃Good
Catalog No. T78295Alias ALXN 6000Cas No. 1073059-33-2
Samalizumab (ALXN 6000) is a humanized anti-CD200 monoclonal antibody that specifically targets the CD200 immunoregulatory cell surface protein, a member of the immunoglobulin superfamily which functions to dampen excessive immune responses and maintain self-tolerance, thereby establishing Samalizumab as an effective immune checkpoint inhibitor currently under investigation for the treatment of myeloma and B-cell chronic lymphocytic leukemia (CLL).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $647 | - | In Stock | |
| 10 mg | $1,200 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:≥95% (SDS-PAGE); 95.64% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Samalizumab (ALXN 6000) is a humanized anti-CD200 monoclonal antibody that specifically targets the CD200 immunoregulatory cell surface protein, a member of the immunoglobulin superfamily which functions to dampen excessive immune responses and maintain self-tolerance, thereby establishing Samalizumab as an effective immune checkpoint inhibitor currently under investigation for the treatment of myeloma and B-cell chronic lymphocytic leukemia (CLL). |
| In vitro | Samalizumab can specifically bind to the immune checkpoint CD200, block receptor binding and signal transduction, and antagonize CD200-driven immunosuppression, thereby mediating anti-tumor immune responses [1]. |
| Synonyms | ALXN 6000 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD200 |
| Molecular Weight | ~150 kDa |
| Cas No. | 1073059-33-2 |
| Isotype | Human IgG4 (S228P) kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Samalizumab | purchase Samalizumab | Samalizumab cost | order Samalizumab | Samalizumab in vitro | Samalizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.